Draft legislation in Germany proposes to allow the G-BA, the body in charge of the pricing and reimbursement process, to request additional registry data from companies marketing orphan drugs, exceptional use products and conditionally approved medicines.
The data will impact on pricing decisions and companies could bear heavy costs for collecting it, according to Eda Zhuleku,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?